Cadila launches allergy relief tablet Dlorfast-M

Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response

Bristol Myers Squibb buys Orbital Therapeutics for $1.5 billion to strengthen cell therapy portfolio

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases

FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder

UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults

Briefs: Panacea Biotec and Shukra Pharmaceuticals

Panacea Biotec receives acceptance from CMSS for supply of bOPV

RedHill Biopharma inks $1.8 million Middle East licensing deal for Talicia

RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months

Biocon and Carnegie receive FDA tentative approval for Rifaximin tablets

Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy

IMCD unveils future of beauty at In-Cosmetics Latin America 2025

IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends

Health Secretary Srivastava chairs meeting with states/UTs on quality and rational use of cough syrups

States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment

AbbVie’s Natrelle awarded supplier agreement from Vizient

This agreement grants Vizient clients enhanced access to Natrelle, the broadest selection of breast implant options on the market

IPA welcomes Dr. Sharvil Patel as President and Glenn Saldanha as Vice President